Mexico Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mexico diabetes care drugs and devices market size was valued at USD 1.87 billion in 2025 and estimated to grow from USD 1.94 billion in 2026 to reach USD 2.36 billion by 2031, at a CAGR of 3.94% during the forecast period (2026-2031). This report is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

Mexico Diabetes Care Drugs And Devices Market Trends and Insights

Rapid Shift Toward Once-Weekly GLP-1 Therapies

Novo Nordisk’s launch of semaglutide 2.4 mg in April 2025 creates a dual-indication opportunity that addresses glycemic control and weight reduction in the same dosing schedule. Evidence from Spanish outpatient settings shows 77.1% of users achieving HbA1c targets below 7%, along with mean weight loss of 9.72 kg, standards now referenced by Mexican specialists. The simplified once-weekly regimen improves adherence compared with daily injections and aligns with employers’ interest in productivity gains, prompting large insurers to pilot formulary coverage in urban centers. COFEPRIS public advisories against unregulated semaglutide sales underscore official intent to secure supply integrity as demand accelerates.

Mobile-First CGM Adoption Through Public Insurance Apps

IMSS’s expansion of smartphone-based follow-up combined with Abbott’s Libre Rio and Lingo over-the-counter CGMs creates a direct-to-patient channel that sidesteps endocrinologist shortages in rural municipalities. The Dulce Wireless Tijuana study recorded HbA1c reductions of 3.0% after 6 months of text-messaging support and real-time glucose alerts. Roll-out across public insurance portals is expected to expand the Mexico diabetes care drugs and devices market by onboarding newly diagnosed patients into continuous monitoring without clinic visits.

COFEPRIS Backlog Delaying Novel Drug Approvals

Average review times for complex biologics extend up to 18 months versus the statutory 30-day target, stalling patient access to next-generation insulins and GLP-1 combinations. A February 2025 memorandum between the patent office and COFEPRIS is meant to streamline dossier verification, yet near-term approvals remain vulnerable to resource constraints within the agency.

Other drivers and restraints analyzed in the detailed report include:

• Government “Pharmacies for Well-being” Bulk Procurement
• Rising Prevalence of Pre-Diabetes in Adolescents
• Counterfeit GLP-1 Products in Informal Channels

Segment Analysis

Devices generated a 4.76% CAGR outlook through 2031, even as drugs preserved 64.25% of Mexico diabetes care drugs and devices market share in 2025. Over-the-counter CGMs such as Abbott’s Libre Rio now retail in high-street pharmacies without prescriptions, expanding penetration beyond endocrinology clinics. Tandem Diabetes Care and Abbott signed a June 2025 agreement to co-develop sensors with ketone detection, responding to diabetic ketoacidosis prevention gaps. At the same time, once-weekly GLP-1 drugs continue to anchor revenue for the pharmaceutical segment, protected by semaglutide patents valid until at least 2031. The interplay of simplified monitoring and extended-release injectables is expected to lift adherence, reduce emergency admissions, and broaden total addressable demand in the Mexico diabetes care drugs and devices market.

Government bulk purchasing influences both categories. Essential insulin analogs are bundled with glucometers at negotiated caps, whereas advanced pumps remain outside standard formularies, relying on private out-of-pocket spend. Nevertheless, pilot reimbursement for continuous subcutaneous insulin infusion in IMSS clinics, evaluated at MXN 478,020 per QALY for HbA1c > 9% patients, shows incremental acceptance for high-cost hardware among severe cases. Consequently, the total Mexico diabetes care drugs and devices market size for devices could narrow the gap with drugs over the forecast window.

Type 2 conditions comprise 90.78% of Mexico diabetes care drugs and devices market size because of sheer prevalence, yet type 1 is projected to post a 4.82% CAGR through 2031. Telemedicine programs for type 1 patients in rural communities delivered cost savings of USD 72.94 per visit and maintained satisfaction similar to in-person endocrinology follow-up. Automated insulin delivery platforms integrated with FreeStyle Libre sensors minimize hypoglycemic episodes and reduce emergency department use, outcomes that are key for public insurers. Persistent gender gaps, however, show women recording higher diagnosis rates than men due to proactive antenatal screening and primary care attendance.

Type 2 management is transitioning from oral monotherapy to combination regimens that include GLP-1 or SGLT2 agents when HbA1c remains uncontrolled. Community-based education among Mayan populations achieved 60% metabolic control versus 35.4% prior baselines. These culturally tailored models are now being replicated in other indigenous regions, signalling that effective localized care can sustain market expansion for both drugs and devices in the Mexico diabetes care drugs and devices market.

Complete Report Scope:

• By Product Type
  • Devices
    • Monitoring Devices
      • Self-Monitoring Blood Glucose Meters
      • Continuous Glucose Monitoring Systems
    • Management Devices
  • Drugs
    • Oral Anti-Diabetic Drugs
    • Insulin Drugs
    • Non-Insulin Injectables
    • Combination Drugs
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Age Group
  • Adult
  • Geriatric
  • Pediatric
• By Distribution Channel
  • Offline
  • Online

List of Companies Covered in this Report:

• Abbott Laboratories
• Medtronic
• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Roche
• Dexcom
• Insulet
• Tandem Diabetes Care
• Ypsomed
• AstraZeneca
• Pfizer
• Beckton Dickinson
• Johnson & Johnson
• Terumo
• Bayer
• OMRON
• Senseonics
• GlaxoSmithKline
• Boehringer Ingelheim

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support